Alberto Gandini
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$4.9MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $4.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Feb 5, 2024 | NIH | SBIR Phase II A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $399K | ACCEL DIAGNOSTICS, LLC |
| Apr 20, 2023 | NIH | SBIR Phase II A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $97K | ACCEL DIAGNOSTICS, LLC |
| Feb 16, 2022 | NIH | SBIR Phase II A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $1.1M | ACCEL DIAGNOSTICS, LLC |
| Feb 3, 2021 | NIH | SBIR Phase II A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $240K | ACCEL DIAGNOSTICS, LLC |
| Sep 1, 2020 | NIH | SBIR Phase I A rapid blood test to aid the triage of patients affected by head injuries. | $224K | ACCEL DIAGNOSTICS, LLC |
| Feb 26, 2019 | NIH | SBIR Phase I A Rapid Non-Invasive Device for Monitoring Preeclampsia in High Risk Pregnancy | $215K | ACCEL DIAGNOSTICS, LLC |
| Jul 26, 2018 | NIH | SBIR Phase II A disposable assay for the monitoring of heart failure in the home setting. | $332K | ACCEL DIAGNOSTICS, LLC |
| Aug 7, 2017 | NIH | SBIR Phase II A disposable assay for the monitoring of heart failure in the home setting. | $944K | ACCEL DIAGNOSTICS, LLC |
| Apr 5, 2017 | NIH | SBIR Phase I I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood. | $49K | ACCEL DIAGNOSTICS, LLC |
| Jun 15, 2016 | NIH | SBIR Phase I I Corps Program for A rapid instrument free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood | $195K | ACCEL DIAGNOSTICS, LLC |
| Jun 14, 2016 | NIH | SBIR Phase I A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood | $145K | ACCEL DIAGNOSTICS, LLC |
| Apr 1, 2015 | NIH | SBIR Phase I A disposable assay for the monitoring of heart failure in the home setting | $225K | ACCEL DIAGNOSTICS, LLC |
| — | NIH | SBIR Phase II SBIR TOPIC 97 - PHASE II - MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY | $727K | ACCEL DIAGNOSTICS, LLC |
Peer ranks
Federal funding#297
Awards as PI#77
Patents#505
Companies
- ACCEL DIAGNOSTICS, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.